221 related articles for article (PubMed ID: 37627069)
1. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
3. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
[TBL] [Abstract][Full Text] [Related]
4. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M
Front Oncol; 2021; 11():686308. PubMed ID: 34820323
[TBL] [Abstract][Full Text] [Related]
5. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
6. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
[TBL] [Abstract][Full Text] [Related]
7. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
8. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
[TBL] [Abstract][Full Text] [Related]
9. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
[TBL] [Abstract][Full Text] [Related]
13. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
15. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
17. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ
ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642
[TBL] [Abstract][Full Text] [Related]
19. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]